BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Phase 2

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Daclatasvir
Drug: Placebo
Drug: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2009-11-20

Last Posted Date: 2015-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 55

Registration Number: NCT01017575

Locations: 🇯🇵
Local Institution, Musashino-Shi, Tokyo, Japan

Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: MDX-1100
Drug: Placebo

First Posted Date: 2009-11-20

Last Posted Date: 2010-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT01017367

Locations: 🇷🇴
"Dr. Carol Davila" Central Military Emergency Clinical Hospital, Bucharest, Romania
🇺🇦
Zaporizhya State Medical University, Department of Internal Diseases #2, Clinical facility: Medical and Sanitary Unit within the State-Owned Company "Radioprylad", Zaporizhya, Ukraine
🇷🇴
"Sf. Pantelimon" Emergency Clinical Hospital, Bucharest, Romania

and more 15 locations

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Phase 2

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Placebo
Drug: BMS-790052
Drug: Peginterferon alfa-2b
Drug: Ribavirin

First Posted Date: 2009-11-20

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 51

Registration Number: NCT01016912

Locations: 🇯🇵
Local Institution, Minato-Ku, Tokyo, Japan

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: BMS-790052
Drug: BMS-650032
Drug: Pegylated-interferon alfa-2a
Drug: Ribavirin

First Posted Date: 2009-11-13

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 215

Registration Number: NCT01012895

Locations: 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸
Carolinas Center For Liver Disease, Statesville, North Carolina, United States

and more 8 locations

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Phase 3

Completed

Conditions: HIV

Interventions: Drug: Tenofovir/Emtricitabine
Drug: Atazanavir
Drug: Atazanavir/Ritonavir
Drug: Lopinavir/ritonavir

First Posted Date: 2009-10-29

Last Posted Date: 2017-05-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 710

Registration Number: NCT01003990

Locations: 🇵🇷
Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
🇺🇸
Sbma Research, Llc, Miami Beach, Florida, United States
🇺🇸
St Francis Memorial Hospital, San Francisco, California, United States

and more 12 locations

Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Subcutaneous (SC) abatacept
Drug: Intravenous (IV) abatacept

First Posted Date: 2009-10-27

Last Posted Date: 2014-02-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT01001832

Locations: 🇯🇵
Local Institution, Shinjuku-Ku, Tokyo, Japan

Drug-Drug Interaction Study With Rifampin

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: BMS-708163
Drug: Rifampin

First Posted Date: 2009-10-27

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT01002079

Locations: 🇮🇳
Local Institution, Bangalore, India

Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Midazolam
Drug: BMS-791325

First Posted Date: 2009-10-16

Last Posted Date: 2014-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT00996879

Locations: 🇺🇸
Wcct Global, Llc, Cypress, California, United States

A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)

Phase 1

Completed

Conditions: Pediatric Solid Tumors

Interventions: Drug: Irinotecan
Drug: Carboplatin

First Posted Date: 2009-10-07

Last Posted Date: 2010-02-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT00990912

Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2009-10-05

Last Posted Date: 2011-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 108

Registration Number: NCT00989235

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy